- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
DaVita HealthCare Partners Inc (DVA)
DaVita HealthCare Partners Inc stock price live, this page displays NYSE DVA stock exchange data. View the DVA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the DaVita HealthCare Partners Inc real time stock price chart below.
What Is the DaVita HealthCare Partners Inc Stock Price Today?
The DaVita HealthCare Partners Inc stock price today is 183.69.
What Is the Stock Symbol for DaVita HealthCare Partners Inc?
The stock symbol for DaVita HealthCare Partners Inc is "DVA."
What Stock Exchange Does DaVita HealthCare Partners Inc Trade On?
DaVita HealthCare Partners Inc is listed and trades on the NYSE stock exchange.
Is DaVita HealthCare Partners Inc a Good Stock to Buy?
Determining whether DaVita HealthCare Partners Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DVA quote. (ISIN: US23918K1088)
What Is the DaVita HealthCare Partners Inc Stock Price Today?
The DaVita HealthCare Partners Inc stock price today is 183.69.
What Is the Stock Symbol for DaVita HealthCare Partners Inc?
The stock symbol for DaVita HealthCare Partners Inc is "DVA."
What Stock Exchange Does DaVita HealthCare Partners Inc Trade On?
DaVita HealthCare Partners Inc is listed and trades on the NYSE stock exchange.
Is DaVita HealthCare Partners Inc a Good Stock to Buy?
Determining whether DaVita HealthCare Partners Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DVA quote. (ISIN: US23918K1088)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
180.55
183.95
52 wk Range
101.00
247.49
DVA is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
180.55183.95
52 wk Range
101.00247.49
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DVA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
218.43
Upside
+18.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
DaVita Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Why is DaVita stock up 2% today?- Investing.com
- Why is DaVita stock up 2% today?
- Investing.com
Why is DaVita stock sliding today?- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Analyst Ratings
3 Buy
4 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 218.43
(+18.91% Upside)
DaVita HealthCare Partners Inc SWOT Analysis
Dialysis Dilemma | DaVita faces treatment volume challenges despite resilient business model, with cybersecurity incidents adding complexity to operational landscape |
Financial Fortitude | Strong profitability and cash flow generation underscore DaVita's financial health, with analysts projecting EPS of $11.79 for FY 2025 |
Strategic Diversification | Explore DaVita's expanding Integrated Kidney Care segment and international operations, which offer growth potential amid core business headwinds |
Market Valuation | With an average price target of $165, DaVita's stock trades near 52-week lows, potentially presenting value for investors amid industry challenges |
DaVita HealthCare Partners Inc Earnings Call Summary for Q2/2026
- DaVita Q2 2026 adjusted EPS of $4.02 beat estimates of $3.84; revenue of $3.55B topped $3.49B forecast, but shares fell 7% after-hours.
- Company reaffirmed full-year guidance with adjusted EPS midpoint of $14.65 and operating income of $2.2B despite margin pressures.
- Revenue per treatment declined $2 sequentially; commercial mix headwind of $40M in 2026 expected to worsen in 2027 amid coverage shifts.
- Treatment volume grew 56 basis points YoY driven by lower mortality rates; Q4 operating income expected up $50M-$100M from Q3.
- Expanded hemodialysis technology rollout underway following FDA approval, but meaningful financial benefits not anticipated until 2028.
Last Updated: 2026-08-04, 05:58 p/m
Read Full TranscriptEarnings
Latest Release
Aug 04, 2026
EPS / Forecast
4.02 / 3.84
Revenue / Forecast
3.55B / 3.49B
Compare DVA to Peers and Sector
Metrics to compare | DVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDVAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.2x | 9.5x | −0.4x | |
PEG Ratio | 0.76 | 0.05 | 0.00 | |
Price/Book | −15.3x | 0.2x | 2.6x | |
Price / LTM Sales | 0.8x | 0.2x | 3.1x | |
Upside (Analyst Target) | 19.7% | 9.1% | 48.5% | |
Fair Value Upside | Unlock | 34.0% | 5.8% | Unlock |
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the DaVita (DVA) Stock Price Today?
The DaVita stock price today is 183.69 USD.
What Stock Exchange Does DaVita Trade On?
DaVita is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for DaVita?
The stock symbol for DaVita is "DVA."
What Is the DaVita Market Cap?
As of today, DaVita market cap is 11.71B USD.
What Is DaVita's Earnings Per Share (TTM)?
The DaVita EPS (TTM) is 12.38.
When Is the Next DaVita Earnings Date?
DaVita will release its next earnings report on Oct 23, 2026.
From a Technical Analysis Perspective, Is DVA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has DaVita Stock Split?
DaVita has split 3 times.
How Many Employees Does DaVita Have?
DaVita has 78000 employees.
What is the current trading status of DaVita (DVA)?
As of Aug 10, 2026, DaVita (DVA) is trading at a price of 183.69 USD, with a previous close of 183.77 USD. The stock has fluctuated within a day range of 180.55 USD to 183.95 USD, while its 52-week range spans from 101.00 USD to 247.49 USD.
What Is DaVita (DVA) Price Target According to Analysts?
The average 12-month price target for DaVita is 218.43 USD, with a high estimate of 270 USD and a low estimate of 165 USD. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +18.91% Upside potential.
What Is the DVA Premarket Price?
DVA's last pre-market stock price is 182.00 USD. The pre-market share volume is 1,230.00, and the stock has decreased by -1.77, or -0.96%.
What Is the DVA After Hours Price?
DVA's last after hours stock price is 184.00 USD, the stock has decreased by 0.31, or 0.17%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.